Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostar with CCRT in Unresectable Stage III NSCLC
NCT01733589Phase 2Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Nov 2012
- Primary completion
- Jun 2015
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of endostar in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Nov 2012; status: completed.
02
Drugs
endostar
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01733589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01733589.